
Gitte Moos Knudsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7903165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain, 2023, 146, 1141-1151.	3.7	30
2	Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology, 2023, 48, 145-150.	2.8	21
3	Neuronal underpinnings of cognitive impairment in bipolar disorder: A large dataâ€driven functional magnetic resonance imaging study. Bipolar Disorders, 2022, 24, 69-81.	1.1	16
4	Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. Journal of Psychopharmacology, 2022, 36, 74-84.	2.0	29
5	Action-based cognitive remediation in bipolar disorder improved verbal memory but had no effect on the neural response during episodic memory encoding. Psychiatry Research - Neuroimaging, 2022, 319, 111418.	0.9	1
6	Influence of pre-treatment structural brain measures on effects of action-based cognitive remediation on executive function in partially or fully remitted patients with bipolar disorder. European Neuropsychopharmacology, 2022, 56, 50-59.	0.3	5
7	Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene Egr3. Molecular Psychiatry, 2022, 27, 1599-1610.	4.1	8
8	PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. Scientific Data, 2022, 9, 65.	2.4	20
9	The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study. Frontiers in Endocrinology, 2022, 13, 799675.	1.5	5
10	An in vivo Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates. Frontiers in Neuroscience, 2022, 16, 847074.	1.4	3
11	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology, 2022, 13, 841648.	1.6	29
12	Neural underpinnings of emotion regulation subgroups in remitted patients with recently diagnosed bipolar disorder. European Neuropsychopharmacology, 2022, 60, 7-18.	0.3	6
13	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neuroscience and Biobehavioral Reviews, 2022, 138, 104689.	2.9	45
14	Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression. Translational Psychiatry, 2022, 12, 204.	2.4	11
15	Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study. Brain Sciences, 2022, 12, 654.	1.1	1
16	Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. Journal of Psychopharmacology, 2022, 36, 626-636.	2.0	11
17	Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study. Translational Psychiatry, 2022, 12, .	2.4	7
18	An fMRI-compatible system for targeted electrical stimulation. Journal of Neuroscience Methods, 2022, 378, 109659.	1.3	0

#	Article	IF	CITATIONS
19	Trajectory of aberrant reward processing in patients with bipolar disorder – A longitudinal fMRI study. Journal of Affective Disorders, 2022, 312, 235-244.	2.0	4
20	Nondisplaceable Binding Is a Potential Confounding Factor in ¹¹ C-PBR28 Translocator Protein PET Studies. Journal of Nuclear Medicine, 2021, 62, 412-417.	2.8	10
21	Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin. Neuropsychopharmacology, 2021, 46, 257-258.	2.8	9
22	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 2021, 35, 459-468.	2.0	40
23	Change in prefrontal activity and executive functions after action-based cognitive remediation in bipolar disorder: a randomized controlled trial. Neuropsychopharmacology, 2021, 46, 1113-1121.	2.8	19
24	Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. European Neuropsychopharmacology, 2021, 42, 1-11.	0.3	19
25	Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors. Supportive Care in Cancer, 2021, 29, 3319-3328.	1.0	5
26	A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. International Journal of Molecular Sciences, 2021, 22, 835.	1.8	96
27	Reward processing in major depressive disorder and prediction of treatment response – Neuropharm study. European Neuropsychopharmacology, 2021, 44, 23-33.	0.3	10
28	Default mode network functional connectivity negatively associated with trait openness to experience. Social Cognitive and Affective Neuroscience, 2021, 16, 950-961.	1.5	12
29	Assessment of the neuronal underpinnings of cognitive impairment in bipolar disorder with a picture encoding paradigm and methodological lessons learnt. Journal of Psychopharmacology, 2021, 35, 983-991.	2.0	6
30	Early stopping in clinical PET studies: How to reduce expense and exposure. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2805-2819.	2.4	1
31	A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors. NeuroImage, 2021, 232, 117878.	2.1	47
32	Trait aggression is associated with fiveâ€factor personality traits in males. Brain and Behavior, 2021, 11, e02175.	1.0	9
33	Structural brain abnormalities associated with cognitive impairments in bipolar disorder. Acta Psychiatrica Scandinavica, 2021, 144, 379-391.	2.2	8
34	Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study. European Neuropsychopharmacology, 2021, 49, 101-112.	0.3	18
35	NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. Journal of Psychiatric Research, 2021, 141, 57-65.	1.5	12
36	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 2021, 50, 121-132.	0.3	57

#	Article	IF	CITATIONS
37	The Modulatory Role of Serotonin on Human Impulsive Aggression. Biological Psychiatry, 2021, 90, 447-457.	0.7	33
38	Affective episodes in recently diagnosed patients with bipolar disorder associated with altered working memory-related prefrontal cortex activity: A longitudinal fMRI study. Journal of Affective Disorders, 2021, 295, 647-656.	2.0	8
39	Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2098238.	2.4	16
40	Reply to: Aberrant Brain Activity in Individuals With Psychopathy Links to Receptor Distribution, Gene Expression, and Behavior. Biological Psychiatry, 2021, , .	0.7	0
41	Synaptic Density and Neuronal Metabolic Function Measured by Positron Emission Tomography in the Unilateral 6-OHDA Rat Model of Parkinson's Disease. Frontiers in Synaptic Neuroscience, 2021, 13, 715811.	1.3	16
42	P.0828 Psilocybin enhances emotional response to music in healthy individuals. European Neuropsychopharmacology, 2021, 53, S604-S605.	0.3	0
43	P.0692 Oral contraceptives and the serotonin 4 receptor in major depressive disorder: results from the NeuroPharm 1 study. European Neuropsychopharmacology, 2021, 53, S506-S507.	0.3	0
44	P.0593 Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. European Neuropsychopharmacology, 2021, 53, S433-S434.	0.3	0
45	P.0512 Brain serotonin transporter is associated with cognitive affective biases in healthy individuals. European Neuropsychopharmacology, 2021, 53, S377-S378.	0.3	1
46	P.0521 An fMRI-compatible system for targeted electrical stimulation. European Neuropsychopharmacology, 2021, 53, S384-S385.	0.3	0
47	P.0396 Cerebral serotonin 4 receptor binding positively associated with cortisol awakening response in untreated patients with depression: a neuropharm 1 study. European Neuropsychopharmacology, 2021, 53, S285.	0.3	0
48	Different preprocessing strategies lead to different conclusions: A [11C]DASB-PET reproducibility study. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1902-1911.	2.4	10
49	Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 355-365.	3.3	6
50	The structure of the serotonin system: A PET imaging study. NeuroImage, 2020, 205, 116240.	2.1	17
51	Imaging HDACs In Vivo: Cross-Validation of the [11C]Martinostat Radioligand in the Pig Brain. Molecular Imaging and Biology, 2020, 22, 569-577.	1.3	7
52	Radiosynthesis and preclinical evaluation of [¹¹ C]Cimbiâ€701 – Towards the imaging of cerebral 5â€HT ₇ receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 46-55.	0.5	3
53	Towards selective CNS PET imaging of the 5-HT7 receptor system: Past, present and future. Neuropharmacology, 2020, 172, 107830.	2.0	14
54	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology, 2020, 45, 804-810.	2.8	34

#	Article	IF	CITATIONS
55	P.310 Patients with major depressive disorder have lower cerebral serotonin 4 receptor binding than healthy controls. European Neuropsychopharmacology, 2020, 31, S53-S54.	0.3	2
56	Fragment-based labeling using condensation reactions of six potential 5-HT7R PET tracers. Journal of Radioanalytical and Nuclear Chemistry, 2020, 326, 1749-1762.	0.7	0
57	P.223 Link between Serotonin 4 receptor brain binding and cognitive disturbances in major depressive disorder: a NeuroPharm study. European Neuropsychopharmacology, 2020, 40, S127-S128.	0.3	Ο
58	P.383 Effect of Î ² -adrenergic antagonists on the risk of alzheimer's disease amongst hypertensive patients: a nation-wide cohort study. European Neuropsychopharmacology, 2020, 40, S219-S220.	0.3	1
59	False positive rates in positron emission tomography (PET) voxelwise analyses. Journal of Cerebral Blood Flow and Metabolism, 2020, 41, 0271678X2097496.	2.4	5
60	Common <scp><i>HTR2A</i></scp> variants and <scp>5â€HTTLPR</scp> are not associated with human in vivo serotonin <scp>2A</scp> receptor levels. Human Brain Mapping, 2020, 41, 4518-4528.	1.9	19
61	Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol. Frontiers in Psychiatry, 2020, 11, 641.	1.3	30
62	Cognitive impairment and psychopathology in out-of-hospital cardiac arrest survivors in Denmark: The REVIVAL cohort study protocol. BMJ Open, 2020, 10, e038633.	0.8	6
63	Visual stimuli induce serotonin release in occipital cortex: A simultaneous positron emission tomography/magnetic resonance imaging study. Human Brain Mapping, 2020, 41, 4753-4763.	1.9	7
64	Haplotype of the astrocytic water channel AQP4 is associated with slow wave energy regulation in human NREM sleep. PLoS Biology, 2020, 18, e3000623.	2.6	39
65	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. Frontiers in Pharmacology, 2020, 11, 591.	1.6	8
66	Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder. Frontiers in Psychology, 2020, 11, 961.	1.1	6
67	Serotonin transporter gene (<i>SLC6A4</i>) variation and sensory processing sensitivity—Comparison with other anxietyâ€related temperamental dimensions. Molecular Genetics & Genomic Medicine, 2020, 8, e1352.	0.6	14
68	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 2020, 33, 71-80.	0.3	88
69	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. Neurochemistry International, 2020, 138, 104772.	1.9	11
70	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1576-1585.	2.4	47
71	In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [125I]Iodo-ASEM and [18F]ASEM as Radiotracers of Homo- and Heteromeric α7 Nicotinic Acetylcholine Receptors. Molecules, 2020, 25, 1425.	1.7	8
72	Dynamic coupling of whole-brain neuronal and neurotransmitter systems. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9566-9576.	3.3	173

#	Article	IF	CITATIONS
73	Abnormal prefrontal cortex processing of reward prediction errors in recently diagnosed patients with bipolar disorder and their unaffected relatives. Bipolar Disorders, 2020, 22, 849-859.	1.1	4
74	Blocking of efflux transporters in rats improves translational validation of brain radioligands. EJNMMI Research, 2020, 10, 124.	1.1	12
75	Migraine is associated with high brain 5-HT levels as indexed by 5-HT ₄ receptor binding. Cephalalgia, 2019, 39, 526-532.	1.8	12
76	Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions. EJNMMI Research, 2019, 9, 71.	1.1	7
77	In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 352-364.	0.9	5
78	Radiolabeling and in vivo evaluation of [11C]AGH-44: a potential lead structure to develop a positron emission tomography radioligand for the 5-HT7 receptor. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 847-851.	0.7	1
79	Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans. Translational Psychiatry, 2019, 9, 134.	2.4	40
80	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 2019, 33, 1039-1057.	2.0	121
81	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 2019, 44, 1328-1334.	2.8	259
82	A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.4	16
83	Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT _{1B} Receptor Binding. JAMA Neurology, 2019, 76, 834.	4.5	27
84	Synthesis and Pharmacological Evaluation of [¹¹ C]4-Methoxy- <i>N</i> -[2-(thiophen-2-yl)imidazo[1,2- <i>a</i>]pyridin-3-yl]benzamide as a Brain Penetrant PET Ligand Selective for the δ-Subunit-Containing γ-Aminobutyric Acid Type A Receptors. ACS Omega, 2019, 4, 8846-8851.	1.6	7
85	Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [11C]DASB PET study. NeuroImage, 2019, 199, 466-479.	2.1	21
86	Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
87	Synthesis, Radiolabeling, and in Vitro and in Vivo Evaluation of [¹⁸ F]ENL30: A Potential PET Radiotracer for the 5-HT ₇ Receptor. ACS Omega, 2019, 4, 7344-7353.	1.6	10
88	Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. Journal of Psychopharmacology, 2019, 33, 1068-1075.	2.0	37
89	Development and Evaluation of Two Potential 5-HT ₇ Receptor PET Tracers: [¹⁸ F]ENL09 and [¹⁸ F]ENL10. ACS Chemical Neuroscience, 2019, 10, 3961-3968.	1.7	9
90	Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 986-990.	1.0	16

#	Article	IF	CITATIONS
91	Psychometric Properties and Validation of the EMOTICOM Test Battery in a Healthy Danish Population. Frontiers in Psychology, 2019, 10, 2660.	1.1	10
92	P.361 Brain serotonin release reduced among patients with severe depression: a pet study with [11c]cimbi-36 and d-amphetamine challenge. European Neuropsychopharmacology, 2019, 29, S258.	0.3	1
93	P.553 5-HT4R binding is positively correlated with obsessive-compulsive features: a preliminary analysis in healthy volunteers. European Neuropsychopharmacology, 2019, 29, S388-S389.	0.3	0
94	P.870 Danes with seasonal affective disorder downregulate cerebral 5-HT4 receptors in the winter. European Neuropsychopharmacology, 2019, 29, S579-S580.	0.3	0
95	P.302 Healthy women who use oral contraceptives show lower brain serotonin 4 receptor binding relative to nonusers. European Neuropsychopharmacology, 2019, 29, S215.	0.3	0
96	P.182 Imaging histone deacetylases in vivo: cross-validation of the [11C]Martinostat radiotracer in the pig brain. European Neuropsychopharmacology, 2019, 29, S139-S140.	0.3	0
97	P.188 Long-term effects of psilocybin on cerebral serotonin 2A receptor levels and personality. European Neuropsychopharmacology, 2019, 29, S144.	0.3	0
98	P.839 Modelling the acute temporal dynamics of psilocybin psychoactive effects; relation to brain serotonin 2a receptor levels. European Neuropsychopharmacology, 2019, 29, S558.	0.3	0
99	P.846 Genetic haplotype of the glymphatic-associated water channel aquaporin 4 modulates slow waves in human non-rapid eye movement sleep. European Neuropsychopharmacology, 2019, 29, S563-S564.	0.3	0
100	P.489 Resting-state default mode network functional connectivity associations with personality trait openness to experience. European Neuropsychopharmacology, 2019, 29, S343-S344.	0.3	0
101	P.325 Reward anticipation processing in major depressive disorder and prediction of treatment response - a functional magnetic resonance imaging study. European Neuropsychopharmacology, 2019, 29, S233.	0.3	0
102	Evaluation of [¹⁸ F]2FP3 in pigs and nonâ€human primates. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 34-42.	0.5	12
103	Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study. Human Brain Mapping, 2019, 40, 2117-2124.	1.9	8
104	Three weeks of SSRI administration enhances the visual perceptual threshold - a randomized placebo-controlled study. Psychopharmacology, 2019, 236, 1759-1769.	1.5	6
105	Cerebral serotonin transporter measurements with [¹¹ C]DASB: A review on acquisition and preprocessing across 21 PET centres. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 210-222.	2.4	25
106	Amygdala reactivity to fearful faces correlates positively with impulsive aggression. Social Neuroscience, 2019, 14, 162-172.	0.7	18
107	Cortical modulation of pupillary function: systematic review. PeerJ, 2019, 7, e6882.	0.9	38
108	Automated pupillometry to detect command following in neurological patients: a proof-of-concept study. PeerJ, 2019, 7, e6929.	0.9	22

7

#	Article	IF	CITATIONS
109	The utility of employing accuracy-based behavioral measures, when conducting psychopharmacological research of attentional performance. Journal of Vision, 2019, 19, 279c.	0.1	Ο
110	Cerebral serotonin release correlates with [¹¹ C]AZ10419369 PET measures of 5-HT _{1B} receptor binding in the pig brain. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1243-1252.	2.4	13
111	High brain serotonin levels in migraine between attacks: A 5-HT4 receptor binding PET study. NeuroImage: Clinical, 2018, 18, 97-102.	1.4	26
112	PET Imaging of the 5-HT2A Receptor System: A Tool to Study the Receptor's In Vivo Brain Function. , 2018, , 85-134.		5
113	Self-perceived personality characteristics in seasonal affective disorder and their implications for severity of depression. Psychiatry Research, 2018, 262, 108-114.	1.7	4
114	Amygdala response to emotional faces in seasonal affective disorder. Journal of Affective Disorders, 2018, 229, 288-295.	2.0	8
115	Five-factor personality is associated with aggression and mental distress in violent offenders. European Neuropsychopharmacology, 2018, 28, S35-S36.	0.3	4
116	Low 5-HT _{1B} receptor binding in the migraine brain: A PET study. Cephalalgia, 2018, 38, 519-527.	1.8	26
117	Men with high serotonin 1B receptor binding respond to provocations with heightened amygdala reactivity. Neurolmage, 2018, 166, 79-85.	2.1	15
118	The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [¹¹ C]Cimbi-36 labeled in two positions. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 659-668.	2.4	23
119	Automatic delineation of brain regions on MRI and PET images from the pig. Journal of Neuroscience Methods, 2018, 294, 51-58.	1.3	27
120	Consciousness in Neurocritical Care Cohort Study Using fMRI and EEG (CONNECT-ME): Protocol for a Longitudinal Prospective Study and a Tertiary Clinical Care Service. Frontiers in Neurology, 2018, 9, 1012.	1.1	12
121	Neuroticism predicts the impact of serotonin challenges on fear processing in subgenual anterior cingulate cortex. Scientific Reports, 2018, 8, 17889.	1.6	12
122	Influence of Strategic Cortical Infarctions on Pupillary Function. Frontiers in Neurology, 2018, 9, 916.	1.1	15
123	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials, 2018, 19, 611.	0.7	16
124	Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD. Current Biology, 2018, 28, 3065-3074.e6.	1.8	159
125	Pre-intervention test-retest reliability of EEG and ERP over four recording intervals. International Journal of Psychophysiology, 2018, 134, 30-43.	0.5	37
126	Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. Trials, 2018, 19, 487.	0.7	18

#	Article	IF	CITATIONS
127	Classics in Neuroimaging: The Serotonergic 2A Receptor System—from Discovery to Modern Molecular Imaging. ACS Chemical Neuroscience, 2018, 9, 1226-1229.	1.7	10
128	Seasonality-resilient individuals downregulate their cerebral 5-HT transporter binding in winter – A longitudinal combined 11C-DASB and 11C-SB207145 PET study. European Neuropsychopharmacology, 2018, 28, 1151-1160.	0.3	10
129	The Impact of Preprocessing Pipeline Choice in Univariate and Multivariate Analyses of PET Data. , 2018, , .		1
130	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open, 2018, 8, e019562.	0.8	22
131	Low on energy? An energy supply-demand perspective on stress and depression. Neuroscience and Biobehavioral Reviews, 2018, 94, 248-270.	2.9	33
132	Serotonin 1B Receptor Binding Is Associated With Trait Anger and Level of Psychopathy in Violent Offenders. Biological Psychiatry, 2017, 82, 267-274.	0.7	41
133	Crowdsourcing for error detection in cortical surface delineations. International Journal of Computer Assisted Radiology and Surgery, 2017, 12, 161-166.	1.7	8
134	Cerebral 5-HT release correlates with [¹¹ C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 425-434.	2.4	31
135	Serotonergic mechanisms in the migraine brain – a systematic review. Cephalalgia, 2017, 37, 251-264.	1.8	68
136	Radiosynthesis and Evaluation of [¹¹ C]3-Hydroxycyclopent-1-enecarboxylic Acid as Potential PET Ligand for the High-Affinity γ-Hydroxybutyric Acid Binding Sites. ACS Chemical Neuroscience, 2017, 8, 22-27.	1.7	8
137	Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3243-3252.	2.4	12
138	Functional MRI for Assessment of the Default Mode Network in Acute Brain Injury. Neurocritical Care, 2017, 27, 401-406.	1.2	37
139	Brain serotonin 4 receptor binding is inversely associated withÂverbal memory recall. Brain and Behavior, 2017, 7, e00674.	1.0	13
140	Genomeâ€wideâ€analyses of <i>Listeria monocytogenes</i> from foodâ€processing plants reveal clonal diversity and date the emergence of persisting sequence types. Environmental Microbiology Reports, 2017, 9, 428-440.	1.0	54
141	Anterior cingulate serotonin 1B receptor binding is associated with emotional response inhibition. Journal of Psychiatric Research, 2017, 92, 199-204.	1.5	9
142	Violent offenders respond to provocations with high amygdala and striatal reactivity. Social Cognitive and Affective Neuroscience, 2017, 12, 802-810.	1.5	61
143	Serotonergic neurotransmission in affective disorders. European Neuropsychopharmacology, 2017, 27, S48-S49.	0.3	0
144	Testosterone levels in healthy men correlate negatively with serotonin 4 receptor binding. Psychoneuroendocrinology, 2017, 81, 22-28.	1.3	28

9

#	Article	IF	CITATIONS
145	A High-Resolution <i>In Vivo</i> Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	1.7	8
146	Functional Characterization of 5-HT _{1B} Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR. Journal of Neuroscience, 2017, 37, 10671-10678.	1.7	16
147	Synthesis, radiofluorination, and preliminary evaluation of the potential 5â€HT _{2A} receptor agonists [¹⁸ F]Cimbiâ€92 and [¹⁸ F]Cimbiâ€150. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 586-591.	0.5	2
148	Season-independent cognitive deficits in seasonal affective disorder and their relation to depressive symptoms. Psychiatry Research, 2017, 257, 219-226.	1.7	12
149	Aggressionâ€related brain function assessed with the Point Subtraction Aggression Paradigm in fMRI. Aggressive Behavior, 2017, 43, 601-610.	1.5	34
150	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	0.8	119
151	A High-Resolution <i>In Vivo</i> Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	1.7	262
152	The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo ¹²³ I-CLINDE SPECT Imaging: A Test–Retest Study. Journal of Nuclear Medicine, 2017, 58, 989-995.	2.8	7
153	Pharmacologically Induced Sex Hormone Fluctuation Effects on Resting-State Functional Connectivity in a Risk Model for Depression: A Randomized Trial. Neuropsychopharmacology, 2017, 42, 446-453.	2.8	31
154	Development of a simple proton nuclear magnetic resonance-based procedure to estimate the approximate distribution coefficient at physiological pH (log D 7.4): Evaluation and comparison to existing practices. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 319-322.	1.0	5
155	Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain. International Journal of Neuropsychopharmacology, 2017, 20, 683-691.	1.0	25
156	Neuroticism Associates with Cerebral in Vivo Serotonin Transporter Binding Differently in Males and Females. International Journal of Neuropsychopharmacology, 2017, 20, 963-970.	1.0	19
157	The Influence of the Toxin/Antitoxin mazEF on Growth and Survival of Listeria monocytogenes under Stress. Toxins, 2017, 9, 31.	1.5	32
158	Brain Networks Implicated in Seasonal Affective Disorder: A Neuroimaging PET Study of the Serotonin Transporter. Frontiers in Neuroscience, 2017, 11, 614.	1.4	9
159	State-dependent alterations in inhibitory control and emotional face identification in seasonal affective disorder Journal of Abnormal Psychology, 2017, 126, 291-300.	2.0	11
160	Design of Infusion Schemes for Neuroreceptor Imaging: Application to [¹¹ C]Flumazenil-PET Steady-State Study. BioMed Research International, 2016, 2016, 1-8.	0.9	6
161	The Small Colony Variant of Listeria monocytogenes Is More Tolerant to Antibiotics and Has Altered Survival in RAW 264.7 Murine Macrophages. Frontiers in Microbiology, 2016, 7, 1056.	1.5	19
162	Sublethal Concentrations of Antibiotics Cause Shift to Anaerobic Metabolism in Listeria monocytogenes and Induce Phenotypes Linked to Antibiotic Tolerance. Frontiers in Microbiology, 2016, 7, 1091.	1.5	30

#	Article	IF	CITATIONS
163	Effects of erythropoietin on memoryâ€relevant neurocircuitry activity and recall in mood disorders. Acta Psychiatrica Scandinavica, 2016, 134, 249-259.	2.2	27
164	Anterior cingulate serotonin 1B receptor binding is positively associated with inhibitory control and amygdala reactivity to aversive faces. European Neuropsychopharmacology, 2016, 26, S329-S330.	0.3	2
165	Neural correlates of improved executive function following erythropoietin treatment in mood disorders. Psychological Medicine, 2016, 46, 1679-1691.	2.7	34
166	Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?. European Neuropsychopharmacology, 2016, 26, 1248-1250.	0.3	25
167	Synthesis and evaluation of 18F-labeled 5-HT2A receptor agonists as PET ligands. Nuclear Medicine and Biology, 2016, 43, 455-462.	0.3	18
168	Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use. Journal of Psychopharmacology, 2016, 30, 1296-1304.	2.0	6
169	A regularized full reference tissue model for PET neuroreceptor mapping. NeuroImage, 2016, 139, 405-414.	2.1	9
170	Autoradiographic imaging and quantification of the high-affinity GHB binding sites in rodent brain using 3H-HOCPCA. Neurochemistry International, 2016, 100, 138-145.	1.9	12
171	Personality traits in Huntington's disease: An exploratory study of gene expansion carriers and nonâ€carriers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1153-1160.	1.1	6
172	Convergent 18F-labeling and evaluation of N-benzyl-phenethylamines as 5-HT2A receptor PET ligands. Bioorganic and Medicinal Chemistry, 2016, 24, 5353-5356.	1.4	13
173	Bright-light intervention induces a dose-dependent increase in striatal response to risk in healthy volunteers. Neurolmage, 2016, 139, 37-43.	2.1	7
174	High trait aggression in men is associated with low 5-HT levels, as indexed by 5-HT 4 receptor binding. Social Cognitive and Affective Neuroscience, 2016, 11, 548-555.	1.5	35
175	Threat-related amygdala functional connectivity is associated with 5-HTTLPR genotype and neuroticism. Social Cognitive and Affective Neuroscience, 2016, 11, 140-149.	1.5	37
176	Seasonal difference in brain serotonin transporter binding predicts symptom severity in patients with seasonal affective disorder. Brain, 2016, 139, 1605-1614.	3.7	60
177	Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin. NeuroImage, 2016, 130, 167-174.	2.1	61
178	Brain serotonin 4 receptor binding is associated with the cortisol awakening response. Psychoneuroendocrinology, 2016, 67, 124-132.	1.3	17
179	Evaluation of acute tryptophan depletion and sham depletion with a gelatin-based collagen peptide protein mixture. European Neuropsychopharmacology, 2016, 26, 147-149.	0.3	3
180	Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. Neurolmage, 2016, 132, 334-343.	2.1	216

#	Article	IF	CITATIONS
181	Sex hormone manipulation slows reaction time and increases labile mood in healthy women. Psychoneuroendocrinology, 2016, 68, 39-46.	1.3	12
182	Metabolic Fate of Hallucinogenic NBOMes. Chemical Research in Toxicology, 2016, 29, 96-100.	1.7	42
183	Development and psychometric validation of the verbal affective memory test. Memory, 2016, 24, 1208-1223.	0.9	26
184	Sex-Steroid Hormone Manipulation Reduces Brain Response to Reward. Neuropsychopharmacology, 2016, 41, 1057-1065.	2.8	46
185	The Center for Integrated Molecular Brain Imaging (Cimbi) database. NeuroImage, 2016, 124, 1213-1219.	2.1	95
186	Molecular Neuroimaging Genetics. , 2016, , 15-30.		0
187	Open and Calm – A randomized controlled trial evaluating a public stress reduction program in Denmark. BMC Public Health, 2015, 15, 1245.	1.2	18
188	Current radiosynthesis strategies for 5â€HT _{2A} receptor PET tracers. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 265-273.	0.5	17
189	Similar serotonin-2A receptor binding in rats with different coping styles or levels of aggression. Synapse, 2015, 69, 226-232.	0.6	5
190	Impaired oxidative capacity due to decreased CPT1b levels as a contributing factor to fat accumulation in obesity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R973-R982.	0.9	24
191	Functional connectivity of the dorsal and median raphe nuclei at rest. NeuroImage, 2015, 116, 187-195.	2.1	85
192	Familial Risk for Major Depression is Associated with Lower Striatal 5-HT4 Receptor Binding. International Journal of Neuropsychopharmacology, 2015, 18, pyu034-pyu034.	1.0	35
193	BDNF Val66met and 5-HTTLPR polymorphisms predict a human in vivo marker for brain serotonin levels. Human Brain Mapping, 2015, 36, 313-323.	1.9	24
194	11C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1053-1056.	1.0	15
195	The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry,the, 2015, 2, 743-755.	3.7	140
196	Radiosynthesis and in vitro validation of 3H-NS14492 as a novel high affinity alpha7 nicotinic receptor radioligand. European Journal of Pharmacology, 2015, 762, 35-41.	1.7	9
197	Fluctuations in [11C]SB207145 PET Binding Associated with Change in Threat-Related Amygdala Reactivity in Humans. Neuropsychopharmacology, 2015, 40, 1510-1518.	2.8	23
198	Role of Serotonin Transporter Changes in Depressive Responses to Sex-Steroid Hormone Manipulation: A Positron Emission Tomography Study. Biological Psychiatry, 2015, 78, 534-543.	0.7	108

#	Article	IF	CITATIONS
199	Evaluation of 3-Ethyl-3-(phenylpiperazinylbutyl)oxindoles as PET Ligands for the Serotonin 5-HT ₇ Receptor: Synthesis, Pharmacology, Radiolabeling, and in Vivo Brain Imaging in Pigs. Journal of Medicinal Chemistry, 2015, 58, 3631-3636.	2.9	32
200	Labeling and preliminary in vivo evaluation of the 5-HT7 receptor selective agonist [11C]E-55888. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1901-1904.	1.0	13
201	5â€HTTLPR differentially predicts brain network responses to emotional faces. Human Brain Mapping, 2015, 36, 2842-2851.	1.9	14
202	TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between ¹²³ I-CLINDE SPECT, ¹⁸ F-FET PET, and Gadolinium-Enhanced MR Imaging. Journal of Nuclear Medicine, 2015, 56, 1386-1390.	2.8	41
203	Central 5-HT Neurotransmission Modulates Weight Loss following Gastric Bypass Surgery in Obese Individuals. Journal of Neuroscience, 2015, 35, 5884-5889.	1.7	36
204	The effect of storage conditions on salivary cortisol concentrations using an Enzyme Immunoassay. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 92-95.	0.6	31
205	A single exposure to a sublethal pediocin concentration initiates a resistanceâ€associated temporal cell envelope and general stress response in <scp><i>L</i></scp> <i>isteria monocytogenes</i> . Environmental Microbiology, 2015, 17, 1134-1151.	1.8	23
206	In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4â€2- ¹²³ I-Iodophenyl)-3-(<i>N,N-</i> Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT. Journal of Nuclear Medicine, 2014, 55, 1966-1972.	2.8	16
207	In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users. International Journal of Neuropsychopharmacology, 2014, 17, 1119-1128.	1.0	16
208	Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients. International Journal of Neuropsychopharmacology, 2014, 17, 1729-1736.	1.0	22
209	Acute social defeat does not alter cerebral 5â€HT _{2A} receptor binding in male Wistar rats. Synapse, 2014, 68, 379-386.	0.6	9
210	Improved resolution and reliability in dynamic PET using Bayesian regularization of MRTM2. , 2014, , .		0
211	Altered reward processing in the orbitofrontal cortex and hippocampus in healthy first-degree relatives of patients with depression. Psychological Medicine, 2014, 44, 1183-1195.	2.7	24
212	Does Harm Avoidance mediate effects of recollected parental bonding on mental distress in adulthood?. Comprehensive Psychiatry, 2014, 55, 1007-1014.	1.5	7
213	Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Molecular Psychiatry, 2014, 19, 427-432.	4.1	80
214	Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT7 receptor. Bioorganic and Medicinal Chemistry, 2014, 22, 1736-1750.	1.4	22
215	Personality characteristics in surgery seeking and non-surgery seeking obese individuals compared to non-obese controls. Eating Behaviors, 2014, 15, 595-598.	1.1	9
216	Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT ₇ Receptors. Journal of Nuclear Medicine, 2014, 55, 640-646.	2.8	37

#	Article	IF	CITATIONS
217	Sweet taste sensitivity is influenced by 5-HTTLPR genotype and affected in seasonal affective disorder. Psychiatry Research, 2014, 220, 727-729.	1.7	3
218	Accelerating preclinical PET-screening: reductive amination with [11C]methoxybenzaldehydes. RSC Advances, 2014, 4, 21347-21350.	1.7	10
219	Simultaneous fMRI–PET of the opioidergic pain system in human brain. NeuroImage, 2014, 102, 275-282.	2.1	59
220	P.1.i.037 Patients with seasonal affective disorder show seasonal fluctuations in their cerebral serotonin transporter binding. European Neuropsychopharmacology, 2014, 24, S319.	0.3	5
221	P.1.g.100 Validation of the extended simplified reference tissue model for pharmacological within-scan challenges in dynamic PET. European Neuropsychopharmacology, 2014, 24, S262-S263.	0.3	2
222	Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. NeuroImage, 2014, 84, 342-353.	2.1	60
223	Serotonin 2A Receptor Agonist Binding in the Human Brain with [¹¹ C]Cimbi-36. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1188-1196.	2.4	88
224	Three-Week Bright-Light Intervention Has Dose-Related Effects on Threat-Related Corticolimbic Reactivity and Functional Coupling. Biological Psychiatry, 2014, 76, 332-339.	0.7	34
225	Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. NeuroImage, 2014, 92, 225-236.	2.1	179
226	11C-labeling and preliminary evaluation of vortioxetine as a PET radioligand. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2408-2411.	1.0	16
227	5-HT2A and mGlu2 receptor binding levels are related to differences in impulsive behavior in the Roman Low- (RLA) and High- (RHA) avoidance rat strains. Neuroscience, 2014, 263, 36-45.	1.1	60
228	Synthesis, radiolabeling and inÂvivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor. European Journal of Medicinal Chemistry, 2014, 79, 152-163.	2.6	26
229	Association of central serotonin transporter availability and body mass index in healthy Europeans. European Neuropsychopharmacology, 2014, 24, 1240-1247.	0.3	34
230	Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males. NeuroImage, 2014, 99, 434-442.	2.1	19
231	Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders. , 2014, , 669-686.		2
232	The 5â€HT ₄ receptor levels in hippocampus correlates inversely with memory test performance in humans. Human Brain Mapping, 2013, 34, 3066-3074.	1.9	51
233	5â€HT radioligands for human brain imaging with PET and SPECT. Medicinal Research Reviews, 2013, 33, 54-111.	5.0	138
234	No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [1231]FP-CIT (DaTSCAN) and SPECT. EJNMMI Research, 2013, 3, 39.	1.1	21

#	Article	IF	CITATIONS
235	Serotonin 2A receptors contribute to the regulation of risk-averse decisions. Neurolmage, 2013, 83, 35-44.	2.1	36
236	European multicentre database of healthy controls for [1231]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 213-227.	3.3	198
237	Playing it safe but losing anyway—Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. European Neuropsychopharmacology, 2013, 23, 919-930.	0.3	39
238	Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response. European Neuropsychopharmacology, 2013, 23, 285-294.	0.3	34
239	ClpP deletion causes attenuation of Salmonella Typhimurium virulence through mis-regulation of RpoS and indirect control of CsrA and the SPI genes. Microbiology (United Kingdom), 2013, 159, 1497-1509.	0.7	49
240	Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36. Molecular Imaging and Biology, 2013, 15, 376-383.	1.3	43
241	Non-essential genes form the hubs of genome scale protein function and environmental gene expression networks in Salmonella entericaserovar Typhimurium. BMC Microbiology, 2013, 13, 294.	1.3	11
242	Development of a 11C-labeled tetrazine for rapid tetrazine–trans-cyclooctene ligation. Chemical Communications, 2013, 49, 3805.	2.2	60
243	Comparison of heat stress responses of immobilized and planktonic Salmonella enterica serovar Typhimurium. Food Microbiology, 2013, 33, 221-227.	2.1	18
244	Palladium-mediated conversion of para-aminoarylboronic esters into para-aminoaryl-11C-methanes. Tetrahedron Letters, 2013, 54, 213-216.	0.7	20
245	Acute pharmacologically induced shifts in serotonin availability abolish emotion-selective responses to negative face emotions in distinct brain networks. European Neuropsychopharmacology, 2013, 23, 368-378.	0.3	37
246	P.1.i.017 Three week bright-light intervention has dose-related effects on threat-related corticolimbic reactivity and functional coupling. European Neuropsychopharmacology, 2013, 23, S272-S273.	0.3	0
247	Cerebral 5-HT2A receptor binding, but not mCluR2, is increased in tryptophan hydroxylase 2 decrease-of-function mice. Neuroscience Letters, 2013, 555, 118-122.	1.0	15
248	Trait aggression and trait impulsivity are not related to frontal cortex 5-HT2A receptor binding in healthy individuals. Psychiatry Research - Neuroimaging, 2013, 212, 125-131.	0.9	33
249	P.1.g.044 Effects of pharmacologically induced sex-hormone fluctuations on emotional processing of faces in healthy women. European Neuropsychopharmacology, 2013, 23, S214-S215.	0.3	0
250	Serotonin 2A Receptors, Citalopram and Tryptophan-Depletion: a Multimodal Imaging Study of their Interactions During Response Inhibition. Neuropsychopharmacology, 2013, 38, 996-1005.	2.8	41
251	Direct comparison of [¹⁸ F]MH.MZ and [¹⁸ F]altanserin for 5â€HT _{2A} receptor imaging with PET. Synapse, 2013, 67, 328-337.	0.6	20
252	Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2013, 54, 1072-1076.	2.8	39

#	Article	IF	CITATIONS
253	No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers. NeuroImage, 2013, 64, 61-67.	2.1	47
254	Radiolabelling and PET brain imaging of the α1-adrenoceptor antagonist Lu AE43936. Nuclear Medicine and Biology, 2013, 40, 135-140.	0.3	17
255	How the cerebral serotonin homeostasis predicts environmental changes: a model to explain seasonal changes of brain 5-HTT as intermediate phenotype of the 5-HTTLPR. Psychopharmacology, 2013, 230, 333-343.	1.5	12
256	Survival of Bactericidal Antibiotic Treatment by a Persister Subpopulation of Listeria monocytogenes. Applied and Environmental Microbiology, 2013, 79, 7390-7397.	1.4	48
257	Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala. Journal of Psychopharmacology, 2013, 27, 903-914.	2.0	20
258	Metabotropic glutamate receptor 2 and corticotrophinâ€releasing factor receptorâ€1 gene expression is differently regulated by BDNF in rat primary cortical neurons. Synapse, 2013, 67, 794-800.	0.6	5
259	Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. Journal of Neuroscience Research, 2013, 91, 634-641.	1.3	31
260	No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [¹²³ I]PE2I. Obesity, 2013, 21, 1803-1806.	1.5	38
261	Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11169-11174.	3.3	112
262	Norquetiapine and Depressive Symptoms in Initially Antipsychotic-Naive First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 266-269.	0.7	7
263	α4βδGABA _A receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13404-13409.	3.3	87
264	Bactericidal Antibiotics Do Not Appear To Cause Oxidative Stress in Listeria monocytogenes. Applied and Environmental Microbiology, 2012, 78, 4353-4357.	1.4	18
265	Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT4 receptor levels. International Journal of Neuropsychopharmacology, 2012, 15, 1099-1107.	1.0	17
266	Subinhibitory concentrations of antibiotics affect stress and virulence gene expression in <i>Listeria monocytogenes</i> and cause enhanced stress sensitivity but do not affect Caco-2 cell invasion. Journal of Applied Microbiology, 2012, 113, 1273-1286.	1.4	19
267	Synthesis and In Vitro Evaluation of Oxindole Derivatives as Potential Radioligands for 5-HT ₇ Receptor Imaging with PET. ACS Chemical Neuroscience, 2012, 3, 1002-1007.	1.7	29
268	Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiology of Aging, 2012, 33, 479-487.	1.5	65
269	Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiology of Aging, 2012, 33, 428.e1-428.e5.	1.5	41
270	Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiology of Aging, 2012, 33, 2334-2342.	1.5	60

#	Article	IF	CITATIONS
271	Cerebral Markers of the Serotonergic System in Rat Models of Obesity and After Rouxâ€en‥ Gastric Bypass. Obesity, 2012, 20, 2133-2141.	1.5	24
272	Synthesis and evaluation of [11C]Cimbi-806 as a potential PET ligand for 5-HT7 receptor imaging. Bioorganic and Medicinal Chemistry, 2012, 20, 4574-4581.	1.4	23
273	Obesity is associated with high serotonin 4 receptor availability in the brain reward circuitry. NeuroImage, 2012, 61, 884-888.	2.1	59
274	5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [11C]SB207145 PET in humans. NeuroImage, 2012, 62, 130-136.	2.1	53
275	Hypothalamic–pituitary–adrenal axis tonus is associated with hippocampal microstructural asymmetry. Neurolmage, 2012, 63, 95-103.	2.1	26
276	No change in [¹¹ C]CUMlâ€101 binding to 5â€HT _{1A} receptors after intravenous citalopram in human. Synapse, 2012, 66, 880-884.	0.6	33
277	Direct radiofluorination of [¹⁸ F]MH.MZ for 5â€HT _{2A} receptor molecular imaging with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 354-358.	0.5	6
278	Simultaneous polysubstance use among Danish 3,4â€methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Human Psychopharmacology, 2012, 27, 352-363.	0.7	31
279	The Microtubule-Associated Protein 1A (MAP1A) is an Early Molecular Target of Soluble Aβ-Peptide. Cellular and Molecular Neurobiology, 2012, 32, 561-566.	1.7	6
280	Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression. Acta Neuropsychiatrica, 2012, 24, 81-90.	1.0	4
281	Cortisol awakening response and negative emotionality linked to asymmetry in major limbic fibre bundle architecture. Psychiatry Research - Neuroimaging, 2012, 201, 63-72.	0.9	40
282	A third mode of surfaceâ€associated growth: immobilization of <i>Salmonella enterica</i> serovar Typhimurium modulates the RpoSâ€directed transcriptional programme. Environmental Microbiology, 2012, 14, 1855-1875.	1.8	27
283	Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 242-250.	3.3	28
284	Blood-Brain Barrier Transport of Lactate. Advances in Neurobiology, 2012, , 755-761.	1.3	3
285	Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: A [11C]DASB PET study. NeuroImage, 2011, 54, 1336-1343.	2.1	26
286	Depression and Alzheimer's Disease: Is Stress the Initiating Factor in a Common Neuropathological Cascade?. Journal of Alzheimer's Disease, 2011, 23, 177-193.	1.2	81
287	Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. Neurochemistry International, 2011, 58, 243-247.	1.9	14
288	Novelty-induced activity-regulated cytoskeletal-associated protein (Arc) expression in frontal cortex requires serotonin 2A receptor activation. Neuroscience, 2011, 190, 251-257.	1.1	14

#	Article	IF	CITATIONS
289	Mass dose effects and in vivo affinity in brain PET receptor studies — a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nuclear Medicine and Biology, 2011, 38, 1085-1091.	0.3	48
290	Blood BDNF concentrations reflect brain-tissue BDNF levels across species. International Journal of Neuropsychopharmacology, 2011, 14, 347-353.	1.0	533
291	P.3.017 In vivo measurements of brain serotonergic markers and analysis of drug use profiles among recreational ecstasy and hallucinogen users. European Neuropsychopharmacology, 2011, 21, S72-S73.	0.3	0
292	P.3.019 Frontal cortex serotonin transporter binding is positively associated with basal physiological stress reactivity in healthy volunteers. European Neuropsychopharmacology, 2011, 21, S74.	0.3	0
293	The Reduction of Baseline Serotonin 2A Receptors in Mild Cognitive Impairment is Stable at Two-year Follow-up. Journal of Alzheimer's Disease, 2011, 23, 453-459.	1.2	24
294	Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 457-466.	1.2	63
295	Survival of Salmonella on cuts of beef carcasses subjected to dry aging. Journal of Applied Microbiology, 2011, 111, 848-854.	1.4	13
296	Age and sex effects on 5-HT ₄ receptors in the human brain: A [¹¹ C]SB207145 PET study. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1475-1481.	2.4	72
297	A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study. Molecular Psychiatry, 2011, 16, 584-585.	4.1	19
298	Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 681-693.	3.3	115
299	Cognitive function is related to fronto-striatal serotonin transporter levels – a brain PET study in young healthy subjects. Psychopharmacology, 2011, 213, 573-581.	1.5	41
300	Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology, 2011, 213, 583-592.	1.5	38
301	An approach for serotonin depletion in pigs: Effects on serotonin receptor binding. Synapse, 2011, 65, 136-145.	0.6	18
302	Ex vivo evaluation of the serotonin 1A receptor partial agonist [³ H]CUMIâ€101 in awake rats. Synapse, 2011, 65, 715-723.	0.6	8
303	Synthesis and biological evaluation of ¹²⁵ I/ ¹²³ I″abelled analogues of citalopram and escitalopram as potential radioligands for imaging of the serotonin transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 185-190.	0.5	2
304	Cognitive testing of pigs (Sus scrofa) in translational biobehavioral research. Neuroscience and Biobehavioral Reviews, 2011, 35, 437-451.	2.9	97
305	¹¹ C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements. Journal of Nuclear Medicine, 2011, 52, 1449-1456.	2.8	56
306	In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasyâ€) and Hallucinogen Users. Archives of General Psychiatry, 2011, 68, 562.	13.8	76

#	Article	IF	CITATIONS
307	Validation of a Method for Accurate and Highly Reproducible Quantification of Brain Dopamine Transporter SPECT Studies. Journal of Nuclear Medicine Technology, 2011, 39, 271-278.	0.4	13
308	Gene variations in the cholecystokinin system in patients with panic disorder. Psychiatric Genetics, 2010, 20, 59-64.	0.6	27
309	Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET. Journal of Nuclear Medicine, 2010, 51, 1763-1770.	2.8	48
310	Hippocampal volume changes in healthy subjects at risk of unipolar depression. Journal of Psychiatric Research, 2010, 44, 655-662.	1.5	70
311	Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding. Psychoneuroendocrinology, 2010, 35, 1311-1320.	1.3	35
312	Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials, 2010, 11, 97.	0.7	42
313	Aging and depression vulnerability interaction results in decreased serotonin innervation associated with reduced BDNF levels in hippocampus of rats bred for learned helplessness. Synapse, 2010, 64, 561-565.	0.6	28
314	Research Letter: Structural Combination of Established 5â€HT _{2A} Receptor Ligands: New Aspects of the Binding Mode. Chemical Biology and Drug Design, 2010, 76, 361-366.	1.5	5
315	Cerebral Blood Flow Response to Functional Activation. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 2-14.	2.4	214
316	Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1682-1706.	2.4	132
317	Cerebral 5-HT _{2A} Receptor and Serotonin Transporter Binding in Humans Are Not Affected by the val66met BDNF Polymorphism Status or Blood BDNF Levels. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, e1-e7.	2.4	13
318	Plaque Deposition Dependent Decrease in 5-HT2A Serotonin Receptor in AβPPswe/PS1dE9 Amyloid Overexpressing Mice. Journal of Alzheimer's Disease, 2010, 20, 1201-1213.	1.2	29
319	Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia. Archives of General Psychiatry, 2010, 67, 9.	13.8	105
320	Novel Radioiodinated γ-Hydroxybutyric Acid Analogues for Radiolabeling and Photolinking of High-Affinity γ-Hydroxybutyric Acid Binding Sites. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 458-464.	1.3	16
321	Procedure Guideline for Brain Perfusion SPECT Using 99mTc Radiopharmaceuticals 3.0. Journal of Nuclear Medicine Technology, 2010, 38, 209-209.	0.4	6
322	Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands ¹²³ I-FP-CIT and ¹²³ I-PE2I. Journal of Nuclear Medicine, 2010, 51, 1885-1891.	2.8	63
323	A Nonlinear Relationship between Cerebral Serotonin Transporter and 5-HT _{2A} Receptor Binding: An <i>In Vivo</i> Molecular Imaging Study in Humans. Journal of Neuroscience, 2010, 30, 3391-3397.	1.7	52
324	Cocaine is pharmacologically active in the nonhuman primate fetal brain. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1582-1587.	3.3	19

#	Article	IF	CITATIONS
325	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. Neuropsychopharmacology, 2010, 35, 1129-1137.	2.8	49
326	Seasonal Changes in Brain Serotonin Transporter Binding in Short Serotonin Transporter Linked Polymorphic Region-Allele Carriers but Not in Long-Allele Homozygotes. Biological Psychiatry, 2010, 67, 1033-1039.	0.7	113
327	SEROTONIN2A RECEPTOR BLOCKADE AND CLINICAL EFFECT IN FIRST-EPISODE SCHIZOPHRENIA PATIENTS TREATED WITH QUETIAPINE. Schizophrenia Research, 2010, 117, 497.	1.1	1
328	Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. NeuroImage, 2010, 50, 855-861.	2.1	79
329	Cerebral serotonin transporter binding is inversely related to body mass index. NeuroImage, 2010, 52, 284-289.	2.1	96
330	5-HT4 receptor binding in hippocampus or prefrontal cortex is not associated with long-term memory test performance. Neurolmage, 2010, 52, S59.	2.1	0
331	Binding saturation with the serotonin 1A receptor agonist [H-3]CUMI-101 and the antagonist [H-3]MPPF, in awake rats. NeuroImage, 2010, 52, S70.	2.1	0
332	Tracer-dose limits and in vivo 5-HT4 receptor affinity in human brain PET studies with [11C]SB207145. NeuroImage, 2010, 52, S193.	2.1	1
333	Genetic variants and brain binding potentials: Lost in translation?. NeuroImage, 2010, 52, S27.	2.1	0
334	Changes in 5-HT4 receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice. Neurochemistry International, 2010, 56, 603-610.	1.9	29
335	Effects of the 5-HT4 receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neuroscience Letters, 2010, 476, 58-61.	1.0	22
336	Changes in 5-HT2A-mediated behavior and 5-HT2A- and 5-HT1A receptor binding and expression in conditional brain-derived neurotrophic factor knock-out mice. Neuroscience, 2010, 169, 1007-1016.	1.1	42
337	Radiosynthesis and ex vivo evaluation of (R)-(â^)-2-chloro-N-[1-11C-propyl]n-propylnorapomorphine. Nuclear Medicine and Biology, 2010, 37, 35-40.	0.3	2
338	Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957. Nuclear Medicine and Biology, 2010, 37, 837-843.	0.3	15
339	Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Experimental Neurology, 2010, 222, 70-85.	2.0	23
340	MRI-Guided Region-of-Interest Delineation Is Comparable to Manual Delineation in Dopamine Transporter SPECT Quantification in Patients: A Reproducibility Study. Journal of Nuclear Medicine Technology, 2010, 38, 61-68.	0.4	11
341	An Incomplete TCA Cycle Increases Survival of Salmonella Typhimurium during Infection of Resting and Activated Murine Macrophages. PLoS ONE, 2010, 5, e13871.	1.1	57
342	Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. Journal of Nuclear Medicine, 2009, 50, 900-908.	2.8	84

#	Article	IF	CITATIONS
343	A Probabilistic Approach to Delineating Functional Brain Regions. Journal of Nuclear Medicine Technology, 2009, 37, 91-95.	0.4	9
344	Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport. Drug Metabolism and Disposition, 2009, 37, 635-643.	1.7	305
345	The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology, 2009, 34, 1380-1389.	1.3	46
346	Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 287-293.	3.3	18
347	Testing for radioligand sensitivity to endogenous neurotransmitter release. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 472-474.	3.3	2
348	Evaluation of the Novel 5-HT ₄ Receptor PET Ligand [¹¹ C]SB207145 in the Göttingen Minipig. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 186-196.	2.4	52
349	The brain 5â€HT ₄ receptor binding is downâ€regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. Journal of Neurochemistry, 2009, 109, 1363-1374.	2.1	77
350	Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorganic and Medicinal Chemistry, 2009, 17, 2989-3002.	1.4	38
351	Activation of glucocorticoid receptors increases 5-HT2A receptor levels. Experimental Neurology, 2009, 218, 83-91.	2.0	23
352	A novel spatial Delayed Non-Match to Sample (DNMS) task in the Göttingen minipig. Behavioural Brain Research, 2009, 196, 93-98.	1.2	15
353	Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding. Neuroscience, 2009, 163, 640-645.	1.1	24
354	BDNF downregulates 5-HT2A receptor protein levels in hippocampal cultures. Neurochemistry International, 2009, 55, 697-702.	1.9	27
355	A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation. NeuroImage, 2009, 44, 1001-1007.	2.1	37
356	The personality trait openness is related to cerebral 5-HTT levels. NeuroImage, 2009, 45, 280-285.	2.1	131
357	Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use. NeuroImage, 2009, 46, 23-30.	2.1	87
358	High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. NeuroImage, 2009, 46, 360-366.	2.1	50
359	Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2212-2219.	3.3	9
360	Total synthesis and evaluation of [18F]MHMZ. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1515-1519.	1.0	33

#	Article	IF	CITATIONS
361	The Effect of S. Pneumoniae Bacteremia on Cerebral Blood Flow Autoregulation in Rats. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 126-134.	2.4	19
362	Cerebral Blood Flow Autoregulation in Experimental Liver Failure. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 916-926.	2.4	27
363	Whole blood BDNF levels in healthy twins discordant for affective disorder: Association to life events and neuroticism. Journal of Affective Disorders, 2008, 108, 165-169.	2.0	30
364	Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder. Biological Psychiatry, 2008, 63, 569-576.	0.7	213
365	Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients. Neuropsychopharmacology, 2008, 33, 2435-2441.	2.8	64
366	Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiology of Aging, 2008, 29, 1830-1838.	1.5	107
367	Aβ(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Experimental Neurology, 2008, 210, 164-171.	2.0	87
368	The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. NeuroImage, 2008, 40, 1175-1180.	2.1	32
369	Gender and cognitive performance: Correlations to 5-HT4 receptors in the human brain: A 11C-SB207145-PET study. NeuroImage, 2008, 41, T160.	2.1	0
370	Decreased serotonin-2A binding in MDMA and hallucinogen users: An [18F]altanserin PET study. NeuroImage, 2008, 41, T46.	2.1	2
371	Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. Journal of Nuclear Medicine, 2008, 49, 247-254.	2.8	31
372	Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. International Journal of Neuropsychopharmacology, 2007, 10, 245.	1.0	61
373	The effect of the inter-phase delay interval in the spontaneous object recognition test for pigs. Behavioural Brain Research, 2007, 181, 210-217.	1.2	34
374	Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. Brain Research Bulletin, 2007, 73, 143-149.	1.4	178
375	Selective immunolesion of cholinergic neurons leads to long-term changes in 5-HT2A receptor levels in hippocampus and frontal cortex. Neuroscience Letters, 2007, 428, 47-51.	1.0	8
376	[123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region. NeuroImage, 2007, 34, 1450-1453.	2.1	38
377	Cerebral blood flow autoregulation in early experimental S. pneumoniae meningitis. Journal of Applied Physiology, 2007, 102, 72-78.	1.2	21
378	Neuroimaging of the serotonin reuptake site requires highâ€affinity ligands. Synapse, 2007, 61, 882-888.	0.6	20

#	Article	IF	CITATIONS
379	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1533-1539.	2.4	1,840
380	Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 101-109.	3.3	18
381	Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 910-915.	3.3	39
382	Automatic extraction of VOI data from functional images. NeuroImage, 2006, 31, T91.	2.1	0
383	Longitudinal assessment of cerebral 5-HT2A receptors in normal volunteers. An [18F]-altanserin PET study. NeuroImage, 2006, 31, T101.	2.1	4
384	Serotonin 2A binding in healthy twins genetically predisposed to major depression in comparison with undisposed controls. NeuroImage, 2006, 31, T163.	2.1	0
385	Serotonin 2A binding in neuroleptic-naive schizophrenic patients and healthy controls using PET and [18-F]altanserin. NeuroImage, 2006, 31, T165.	2.1	1
386	Dopamine transporter quantification by [123I]-SPECT—a future paraclinical tool?. NeuroImage, 2006, 31, T182.	2.1	3
387	Serotonin transporter binding is decreased in healthy twins genetically predisposed to major depression in comparison with undisposed twins. NeuroImage, 2006, 31, T183.	2.1	0
388	Central serotonin depletion affects rat brain areas differently: A qualitative and quantitative comparison between different treatment schemes. Neuroscience Letters, 2006, 392, 129-134.	1.0	34
389	Effect of Graded Hyperventilation on Cerebral Metabolism in a Cisterna Magna Blood Injection Model of Subarachnoid Hemorrhage in Rats. Journal of Neurosurgical Anesthesiology, 2006, 18, 18-23.	0.6	5
390	Immunodetection of the serotonin transporter protein is a more valid marker for serotonergic fibers than serotonin. Synapse, 2006, 59, 270-276.	0.6	68
391	Autonomic dysfunction and impaired cerebral autoregulation in cirrhosis. Clinical Autonomic Research, 2006, 16, 208-216.	1.4	33
392	Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Research, 2006, 1073-1074, 262-268.	1.1	7
393	Effects of Porta-Systemic Shunting and Ammonia Infusion on Cerebral Blood Flow Autoregulation in the Rat. Neurocritical Care, 2005, 3, 086-090.	1.2	5
394	Laser Doppler flowmetry is valid for measurement of cerebral blood flow autoregulation lower limit in rats. Experimental Physiology, 2005, 90, 349-355.	0.9	49
395	?7 nicotinic receptor subunit is present on serotonin neurons projecting to hippocampus and septum. Synapse, 2005, 55, 196-200.	0.6	30
396	Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse, 2005, 58, 249-257.	0.6	55

#	Article	IF	CITATIONS
397	Patients with obsessive–compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. International Journal of Neuropsychopharmacology, 2005, 8, 391-401.	1.0	123
398	Cerebral Pressure Autoregulation and Vasoreactivity in the Newborn Rat. Pediatric Research, 2005, 57, 294-298.	1.1	61
399	The relationship between cerebral blood flow and volume in humans. NeuroImage, 2005, 24, 1-11.	2.1	135
400	MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage, 2005, 24, 969-979.	2.1	327
401	Changes in BOLD and ADC weighted imaging in acute hypoxia during sea-level and altitude adapted states. NeuroImage, 2005, 28, 947-955.	2.1	34
402	Cognitive deficits in obsessive–compulsive disorder on tests of frontal lobe functions. Nordic Journal of Psychiatry, 2005, 59, 39-44.	0.7	43
403	Synthesis and binding studies of 2-arylapomorphines. Organic and Biomolecular Chemistry, 2005, 3, 4077.	1.5	29
404	Neuroreceptor expression as surrogate markers for dementias. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S691-S691.	2.4	0
405	Test-retest measurements of 5-HT2A receptors with [18F]altanserin PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S653-S653.	2.4	0
406	Cerebral blood flow autoregulation in a rat model of subarachnoid hemorrhage as determined with laser Doppler flowmetry and the intra-arterial 133xenon method. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S197-S197.	2.4	0
407	Evaluation of the serotonin transporter ligand [123I]ADAM for SPECT studies in humans. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S651-S651.	2.4	Ο
408	PET-FDG study: Regional associations within the cortico-striatal circuits in OCD patients. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S381-S381.	2.4	0
409	Serotonin 2A receptor binding in healthy twins genetically predisposed to major depression in comparison with undisposed controls. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S583-S583.	2.4	0
410	No association between genotypes of the 5-HT2A receptor gene and [18F]altanserin binding as measured with PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S389-S389.	2.4	0
411	Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. Journal of Nuclear Medicine, 2005, 46, 1119-27.	2.8	20
412	A Newborn Rat Model for the Study of Cerebral Hemodynamics by Near-Infrared Spectroscopy and Laser-Doppler Flowmetry in the Immature Brain. Neonatology, 2004, 85, 112-120.	0.9	3
413	Transient Hyperoxia and Residual Cerebrovascular Effects in the Newborn Rat. Pediatric Research, 2004, 55, 380-384.	1.1	6
414	Cerebral Blood Flow and Metabolism During Infusion of Norepinephrine and Propofol in Patients With Bacterial Meningitis. Stroke, 2004, 35, 1333-1339.	1.0	30

#	Article	IF	CITATIONS
415	[18F]altanserin Binding to Human 5HT2A Receptors is Unaltered after Citalopram and Pindolol Challenge. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1037-1045.	2.4	42
416	Imaging of dopamine transporters and D2 receptors in patients with Parkinson?s disease and multiple system atrophy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1631-1638.	3.3	81
417	Gas phase production of[11C]methyl iodide-d3. Synthesis and biological evaluation ofS-[N-methyl-11C]citalopram and deuterated analogues. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 335-348.	0.5	5
418	Characterization of DegU, a response regulator inListeria monocytogenes, involved in regulation of motility and contributes to virulence. FEMS Microbiology Letters, 2004, 240, 171-179.	0.7	65
419	Non-serotonergic dorsal and median raphe projection onto parvalbumin- and calbindin-containing neurons in hippocampus and septum. Neuroscience, 2004, 124, 573-581.	1.1	39
420	No effect of MDMA (ecstasy) on cell death and 5-HT2A receptor density in organotypic rat hippocampal cultures. Neuroscience Letters, 2004, 362, 6-9.	1.0	5
421	Quantitative PET for assessment of cerebral blood flow and glucose consumption under varying physiological conditions. International Congress Series, 2004, 1265, 189-200.	0.2	2
422	Assessment of the precision in co-registration of structural MR images and PET images with localized binding. International Congress Series, 2004, 1265, 275-280.	0.2	17
423	Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. NeuroImage, 2004, 21, 483-493.	2.1	123
424	A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. NeuroImage, 2004, 21, 1105-1113.	2.1	111
425	Interference of anaesthetics with radioligand binding in neuroreceptor studies. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 912-915.	3.3	48
426	The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Research, 2003, 959, 58-67.	1.1	157
427	Cerebral glucose and oxygen metabolism in patients with fulminant hepatic failure. Liver Transplantation, 2003, 9, 1244-1252.	1.3	35
428	Synthesis and biological evaluation of novel carbon-11-labelled analogues of citalopram as potential radioligands for the serotonin transporter. Bioorganic and Medicinal Chemistry, 2003, 11, 3447-3456.	1.4	41
429	Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 985-996.	2.4	91
430	Assessment of neuroreceptor changes in healthy ageing and in Alzheimer's disease with emission tomography. International Congress Series, 2003, 1252, 299-308.	0.2	0
431	Short-term mechanical hyperventilation does not reduce cerebral oxidative metabolism in patients with fulminant hepatic failure (FHF). Journal of Hepatology, 2002, 36, 42-43.	1.8	3
432	Cerebral hemodynamics measured with simultaneous PET and near-infrared spectroscopy in humans. Brain Research, 2002, 954, 183-193.	1.1	103

#	Article	IF	CITATIONS
433	Quantification of [1231]PE2I binding to dopamine transporters with SPET. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 623-631.	3.3	13
434	Cerebral blood flow, oxidative metabolism and cerebrovascular carbon dioxide reactivity in patients with acute bacterial meningitis. Acta Anaesthesiologica Scandinavica, 2002, 46, 567-578.	0.7	27
435	Predosing with the unlabeled "inactive―enantiomer as a tool for improvement of the PET signal. Synapse, 2002, 46, 125-127.	0.6	2
436	Unchanged Cerebral Blood Flow and Oxidative Metabolism after Acclimatization to High Altitude. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 118-126.	2.4	99
437	Cerebral Blood Flow and Oxidative Metabolism during Human Endotoxemia. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1262-1270.	2.4	64
438	A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. British Journal of Pharmacology, 2002, 135, 823-829.	2.7	103
439	Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology, 2001, 121, 1109-1119.	0.6	114
440	Serotonin induces a decrease of 5-HT1A immunoreactivity in organotypic hippocampal cultures. NeuroReport, 2001, 12, 3909-3912.	0.6	2
441	Idiopathic normal-pressure hydrocephalus: evaluation and findings in a multidisciplinary memory clinic. European Journal of Neurology, 2001, 8, 601-611.	1.7	67
442	Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse, 2001, 41, 203-211.	0.6	29
443	Transcranial doppler sonography and internal jugular bulb saturation during hyperventilation in patients with fulminant hepatic failure. Liver Transplantation, 2001, 7, 352-358.	1.3	35
444	S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transplantation, 2001, 7, 964-970.	1.3	34
445	In Vivo Measurement of Haloperidol Affinity to Dopamine D2/D3 Receptors by [1231]IBZM and Single Photon Emission Computed Tomography. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 92-97.	2.4	5
446	The 18F-fluorodeoxyglucose Lumped Constant Determined in Human Brain from Extraction Fractions of 18F-fluorodeoxyglucose and Glucose. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 995-1002.	2.4	31
447	Circulating levels of neuropeptides (cgrp, vip, npy) in patients with fulminant hepatic failure. Neuropeptides, 2001, 35, 174-180.	0.9	8
448	Cerebral Blood Flow in Patients With Chronic Heart Failure Before and After Heart Transplantation. Stroke, 2001, 32, 2530-2533.	1.0	259
449	Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the 1µ4 Allele on Regional Cerebral Blood Flow. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 42-51.	1.2	27
450	Benzodiazepine receptor quantification in Huntington's disease with [1231]iomazenil and SPECT. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 657-661.	0.9	23

#	Article	IF	CITATIONS
451	Blood-Brain Barrier Transport and Brain Metabolism of Glucose during Acute Hyperglycemia in Humans1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1986-1990.	1.8	39
452	Autoregulation of Cerebral Blood Flow in Patients Resuscitated From Cardiac Arrest. Stroke, 2001, 32, 128-132.	1.0	400
453	Blood-Brain Barrier Transport and Brain Metabolism of Glucose during Acute Hyperglycemia in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1986-1990.	1.8	38
454	Effect of Short-Term Hyperventilation on Cerebral Blood Flow Autoregulation in Patients With Acute Bacterial Meningitis. Stroke, 2000, 31, 1116-1122.	1.0	36
455	Dopamine D2 receptor quantification in extrastriatal brain regions using [1231]epidepride with bolus/infusion. Synapse, 2000, 36, 322-329.	0.6	18
456	SPECT tracer [1231]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse, 2000, 38, 338-342.	0.6	37
457	Regional cerebral blood flow during hyperventilation in patients with acute bacterial meningitis. Clinical Physiology, 2000, 20, 399-410.	0.7	12
458	Dependency of cerebral blood flow on mean arterial pressure in patients with acute bacterial meningitis. Critical Care Medicine, 2000, 28, 1027-1032.	0.4	61
459	Cerebral perfusion, cardiac output, and arterial pressure in patients with fulminant hepatic failure. Critical Care Medicine, 2000, 28, 996-1000.	0.4	47
460	Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Multiple Sclerosis Journal, 2000, 6, 226-230.	1.4	47
461	No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes, 1999, 48, 1915-1921.	0.3	140
462	A multidisciplinary memory clinic in a neurological setting: diagnostic evaluation of 400 consecutive patients. European Journal of Neurology, 1999, 6, 279-288.	1.7	37
463	Blood—Brain Barrier Transport and Protein Binding of Flumazenil and Iomazenil in the Rat: Implications for Neuroreceptor Studies. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 948-955.	2.4	8
464	Regional cerebral blood flow during mechanical hyperventilation in patients with fulminant hepatic failure. Hepatology, 1999, 30, 1368-1373.	3.6	40
465	Calculation of the FDG Lumped Constant by Simultaneous Measurements of Global Glucose and FDG Metabolism in Humans. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 154-160.	2.4	55
466	Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. Journal of Hepatology, 1998, 28, 199-203.	1.8	100
467	<title>Cerebral blood volume in humans by NIRS and PET</title> . , 1998, 3194, 306.		1
468	Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Journal of Hepatology, 1997, 27, 231-238.	1.8	30

#	Article	IF	CITATIONS
469	Application of Interhemispheric Index for Transcranial Doppler Sonography Velocity Measurements and Evaluation of Recording Time. Stroke, 1997, 28, 1009-1014.	1.0	25
470	Dissociated cerebral vasoparalysis in acute liver failure. Journal of Hepatology, 1996, 25, 145-151.	1.8	90
471	Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. European Journal of Gastroenterology and Hepatology, 1996, 8, 261-266.	0.8	76
472	Transport of D-Glucose and 2-Fluorodeoxyglucose across the Blood-Brain Barrier in Humans. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 659-666.	2.4	28
473	Cerebral Glucose Metabolism Is Decreased in White Matter Changes in Patients with Phenylketonuria. Pediatric Research, 1996, 40, 21-24.	1.1	33
474	Cerebral blood flow autoregulation and transcranial doppler sonography in patients with cirrhosis. Hepatology, 1995, 22, 730-736.	3.6	63
475	Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. Journal of Inherited Metabolic Disease, 1995, 18, 653-664.	1.7	48
476	Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. Journal of Hepatology, 1995, 23, 212-217.	1.8	99
477	Cerebral blood flow autoregulation and transcranial doppler sonography in patients with cirrhosis*1. Hepatology, 1995, 22, 730-736.	3.6	3
478	Delayed Onset of Fatal Basilar Thrombotic Embolus After Whiplash Injury. Stroke, 1995, 26, 2194-2196.	1.0	23
479	Brain Metabolism during Short-Term Starvation in Humans. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 125-131.	2.4	125
480	Cerebral blood flow autoregulation is absent in rats with thioacetamide-induced hepatic failure. Journal of Hepatology, 1994, 21, 491-495.	1.8	54
481	Transcranial Doppler is valid for determination of the lower limit of cerebral blood flow autoregulation Stroke, 1994, 25, 1985-1988.	1.0	282
482	Atypical visual loss in giant cell arteritis. Acta Ophthalmologica, 1994, 72, 759-764.	0.6	19
483	Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. Hepatology, 1993, 17, 987-992.	3.6	37
484	Estimation of Unidirectional Clearances of FDG and Glucose Across the Blood-Brain Barrier in Man. Advances in Experimental Medicine and Biology, 1993, 331, 25-27.	0.8	2
485	The influence of haematocrit and blood glucose on cerebral blood flow in normal and in diabetic rats. NeuroReport, 1992, 3, 987-989.	0.6	8
486	Kinetic Analysis of the Human Blood-Brain Barrier Transport of Lactate and its Influence by Hypercapnia. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 581-586.	2.4	68

#	ARTICLE	IF	CITATIONS
487	Regional Density of Perfused Capillaries and Cerebral Blood Flow in Untreated Short-Term and Long-Term Streptozotocin Diabetes. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 361-365.	2.4	23
488	Cerebral blood flow response to propranolol in streptozotocin diabetic rats. NeuroReport, 1990, 1, 232-234.	0.6	4
489	Hypothalamic-Pituitary and Thyroid Function in Chronic Alcoholics with Neurological Complications. Alcoholism: Clinical and Experimental Research, 1990, 14, 363-367.	1.4	7
490	No effect of pulsed magnetic stimulation on the blood-brain barrier in rats. Neuroscience, 1990, 38, 277-280.	1.1	21
491	Kinetic analysis of blood-brain barrier transport of d-glucose in man: Quantitative evaluation in the presence of tracer backflux and capillary heterogeneity. Microvascular Research, 1990, 39, 28-49.	1.1	38
492	Impaired βâ€Adrenergic Mediated Cerebral Blood Flow Response in Streptozotocin Diabetic Rats. Basic and Clinical Pharmacology and Toxicology, 1989, 65, 318-320.	0.0	20
493	Blood?Brain Barrier Permeability to Sodium. Modification by Glucose or Insulin?. Journal of Neurochemistry, 1989, 52, 174-178.	2.1	25
494	Myo-inositol normalizes decreased sodium permeability of the blood-brain barrier in streptozotocin diabetes. Neuroscience, 1989, 29, 773-777.	1.1	33
495	Metabolic Disturbances of the Blood-Brain Barrier with Special Emphasis on Glucose and Amino Acid Transport. , 1989, , 575-600.		0
496	Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. Journal of Hepatology, 1988, 6, 187-192.	1.8	46
497	Discordance between the Cortisol Response to Insulin-Hypoglycemia and 30-Minute ACTH Stimulation Test in Chronic Alcoholic Men. Alcoholism: Clinical and Experimental Research, 1987, 11, 323-325.	1.4	16
498	Cation permeability of the blood-brain barrier in streptozotocin-diabetic rats. Diabetologia, 1987, 30, 409-413.	2.9	33
499	Decreased blood-brain barrier permeability to sodium in early experimental diabetes. Diabetes, 1986, 35, 1371-1373.	0.3	19
500	Neural responses during down-regulation of negative emotion in patients with recently diagnosed bipolar disorder and their unaffected relatives. Psychological Medicine, 0, , 1-12.	2.7	1
501	Brain serotonin transporter is associated with cognitiveâ€affective biases in healthy individuals. Human Brain Mapping, 0, , .	1.9	3